Clinical trial NCT02670343: Phlebotomy Study of Testosterone Undecanoate
Official title: Evaluation of Blood Collection Methodology Following Administration of a Single-Dose of an Oral Testosterone Undecanoate Formulation In Hypogonadal Men
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Hypogonadism
Lead sponsor: Clarus Therapeutics, Inc.
Sponsor class: INDUSTRY
First posted: 2016-02-01
Enrollment: 8
Sex: MALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: An open-label, single oral TU dose study was conducted in eight (8) hypogonadal men at a single study site. Each study participant received a single oral TU dose immediately prior to a standardized breakfast meal comprised of 800 to 1000 calories and approximately 30 g of fat. Blood samples were collected 30 minutes prior dose administration and at 0 pre-dose and post dose at the following hours post-dose; 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours.

Detailed description: This open-label, single oral dose, phlebotomy study was designed to clarify the issue of the influence of blood collection tubes on T, DHT, TU and DHTU measurements by collecting blood samples into various collection tubes from a small number of hypogonadal men dosed with a single oral TU dose in the form of a SEDDS formulation.

Eligibility criteria: Inclusion Criteria:

1. Male, 18 to 65 years of age, inclusive, with a diagnosis of hypogonadism and a screening total serum T of \< 300 ng/dL.
2. Adequate venous access to allow blood sample collections via venous cannula.
3. Naïve to androgen-replacement therapy or willing to temporarily cease current T treatment and willing to remain off all forms of T except for study medication throughout study.
4. Voluntarily provide written informed consent to participate in this study.

Exclusion Criteria:

Subjects meeting any of the following exclusion criteria will not be eligible:

1. Significant intercurrent disease (especially liver, kidney, heart disease, uncontrolled diabetes mellitus or psychiatric illness)
2. Abnormal prostate digital rectal examination, elevated PSA (PSA \> 4 ng/mL), AUA Symptom Score ≥ 15 points and/or history of prostate CA.
3. BMI less than 18 kg/m2 or greater than 37 kg/m2
4. Serum transaminases \> 2 times upper limit of normal (ULN) or serum bilirubin \>2.0 mg/dL.
5. History of severe or multiple allergies, or severe adverse drug reaction. A known hypersensitivity to lidocaine or all surgical dressings which may be used in the study procedures.
6. History of abnormal bleeding tendencies or thrombophlebitis unrelated to venipuncture or intravenous cannulation.
7. Oral, topical or buccal T therapy within previous one week, or intramuscular T injection within previous 4 weeks.
8. Parenteral T-undecanoate therapy within the past 6 months.
9. Use of dietary supplements that may increase serum T, within previous 4 weeks.
10. Known malabsorption syndrome and/or current treatment with oral lipase inhibitors, bile acid-binding resins, colestipol, fibric acid derivatives, clofibrate, gemfibrozil, and probucol.
11. Smokers unable to refrain from smoking during required confinement period.
12. History of, or current evidence of, abuse of alcohol or any drug substance.
13. Receipt of any research study drug within 30 days of study.
14. Blood donation within the 12 week period before the initial study dose.
15. Hematocrit less than 35% or greater than 50%.
16. History of clinically significant polycythemia following treatment with a testosterone replacement product.
17. Current use of paroxetine, clomipramine, antiandrogens, estrogens, potent P450 enzyme inducers, or barbiturates.
18. History of uncontrolled sleep apnea.

Primary outcomes:
measure: % of Mean Difference in T Concentration Compared to Plain Collection Tube
timeFrame: Sample collection at -0.5, and 0 hours pre-dose and post-dose samples collected at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12, hours after a single dose of oral TU.
Secondary outcomes:
Other outcomes:
Locations:
city: Torrance
country: United States
facility: Los Angeles Biomedical Research Institute
state: California
Study officials:
affiliation: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
name: Christina Wang, M.D.
role: PRINCIPAL_INVESTIGATOR
References: